Document Detail


Resource Use and Cost Implications of Switching Among Warfarin Formulations in Atrial Fibrillation Patients (December).
MedLine Citation:
PMID:  23150608     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND:Despite the uncertainty surrounding the safety of switching warfarin formulations, limited data exist on the resource use and costs associated with this switching pattern.OBJECTIVE:To evaluate health care resource use and costs associated with switching warfarin formulations among patients with atrial fibrillation (AF) in a managed care organization.METHODS:Patients diagnosed with AF (ICD-9 427.31) between July 2004 and August 2008 and who received warfarin therapy were identified in the HealthCore Integrated Research Database and categorized into 3 groups: users of generic warfarin formulations from a single drug manufacturer (generic-only group), users of branded warfarin formulations only (brand-only group), and patients who used generic and branded warfarin therapy interchangeably or who may have used generic drugs from 1 or more manufacturers (generic/brand switching group). Patients were followed 12 months or longer after their index warfarin prescription date to compare all-cause resource use and costs using multivariable regression analysis.RESULTS:The analysis included 12,908 patients: 71.82% were in the generic-only group, 9.61% were in the brand-only group, and 18.57% were in the generic/brand switching group. Patients in the generic/brand switching group were more likely to be hospitalized (relative risk [RR] = 1.43, p < 0.0001) or to use emergency department services (RR = 1.20, p < 0.01), compared to the brand-only users. Hospitalizations were more likely (RR = 1.26, p < 0.001) to occur among generic-only users versus brand-only users. Adjusted mean pharmacy costs per member per month were lower in the generic/brand switching group compared to the brand-only group ($257 vs $273, p = 0.038), but inpatient costs were higher ($1250 vs $972, p < 0.001), resulting in higher ($2125 vs $1847, p < 0.001) total costs. Generic-only users had lower pharmacy costs compared to brand-only users ($246 vs $273, p < 0.001), but total health care costs trended to be higher in the generic-only group ($1957 vs $1847, p = 0.053).CONCLUSIONS:The use of both generic and branded formulations of warfarin interchangeably, or the use of generics from more than 1 manufacturer, was associated with increased use of all-cause health care resources and total costs in patients with AF.
Authors:
Winghan Jacqueline Kwong; Siddhesh Kamat; Christy Fang
Related Documents :
15649168 - Use of intravenous midazolam and clonidine in cyclical vomiting syndrome: a case report.
22999748 - Safety and feasibility of same-day discharge of patients with unresectable hepatocellul...
24701498 - Comparison of intrathecal dexmedetomidine with buprenorphine as adjuvant to bupivacaine...
18257398 - Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherap...
16552618 - The effect of cannabis on urge incontinence in patients with multiple sclerosis: a mult...
22925498 - Intravesical hyaluronic acid for interstitial cystitis/painful bladder syndrome: a comp...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-13
Journal Detail:
Title:  The Annals of pharmacotherapy     Volume:  -     ISSN:  1542-6270     ISO Abbreviation:  Ann Pharmacother     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9203131     Medline TA:  Ann Pharmacother     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
< Daiichi Sankyo Inc., Parsippany,NJ.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Genetic variants contribute to gene expression variability in humans.
Next Document:  Suboptimal access to primary healthcare among street-based sex workers in southwest Switzerland.